Anxiety and depressive disorders among children and young people following a cancer diagnosis in England: a retrospective cohort study

Background Psychiatric conditions are important survivorship outcomes among children and young people (CYP) diagnosed with cancer. However, many population-based studies have examined hospital contacts only, and estimates of absolute risk can be biased when competing mortality is not accounted for. We estimated absolute risks and relative hazards of clinically recorded anxiety and related disorders, depressive disorders, and first-time psychotropic prescribing. Methods We conducted a population-based matched retrospective cohort study across 1474 general practices in England using Clinical Practice Research Datalink Aurum primary care records linked to Hospital Episode Statistics Admitted Patient Care and mortality records. CYP diagnosed with malignant cancer or any central nervous system tumour at ages 0–24 years between Jan 1, 2000, and Dec 31, 2022, were matched by age, recorded sex, and general practice to up to 20 comparators without cancer at the index date. Primary outcomes were first recorded anxiety and related disorders and depressive disorders; secondary outcomes were first-time psychotropic prescribing. Individuals with pre-index records of the respective outcome were excluded from that outcome analysis. Follow-up ended at outcome occurrence, death, practice deregistration, last data collection, or Dec 31, 2022. We estimated cumulative incidence using the Aalen-Johansen estimator and ethnicity-adjusted cause-specific hazard ratios (HRs) using matched-set stratified Cox models. Findings There were 9145 CYP with cancer and 178709 comparators. Adjusted cause-specific HRs were 1.74 (95% confidence interval [CI] 1.61–1.88) for anxiety and related disorders, 1.16 (1.06–1.26) for depressive disorders, 1.27 (1.20–1.35) for antidepressant prescribing, 2.21 (2.05–2.38) for antipsychotic prescribing, and 2.69 (2.53–2.86) for anxiolytic prescribing. At 15 years, cumulative incidence was 14.1% (95% CI 13.0–15.3) versus 12.8% (12.5–13.1) for anxiety and related disorders, and 12.8% (11.6–14.0) versus 14.1% (13.8–14.5) for depressive disorders. Excess hazards were greatest in the early years after diagnosis. Interpretation CYP diagnosed with cancer had higher hazards of clinically recorded anxiety and related disorders, depressive disorders, and first-time psychotropic prescribing. These findings support proactive mental health monitoring and timely referral pathways within cancer and survivorship care, particularly early after diagnosis. Further research should evaluate whether timely assessment and tailored psychosocial support improve outcomes. Funding National Institute for Health and Care Research Manchester Biomedical Research Centre and Greater Manchester Patient Safety Research Collaboration.

Authors

Institutions

Publication Details

Journal
EClinicalMedicine
Published
2026-11-13
DOI
https://doi.org/10.1016/j.eclinm.2026.104336
Primary Topic
Childhood Cancer Survivors' Quality of Life
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Anxiety and depressive disorders among children and young people following a cancer diagnosis in England: a retrospective cohort study

Martin G. McCabe, Shruti Garg, Darren Mark Ashcroft, Claire Emily Higham et al.
1 links
EClinicalMedicine
Childhood Cancer Survivors' Quality of Life
article

Anxiety and depressive disorders among children and young people following a cancer diagnosis in England: a retrospective cohort study

Martin G. McCabe, Shruti Garg, Darren Mark Ashcroft, Claire Emily Higham, Pearl L. H. Mok, Roger Thomas Webb, Moe Zandy, Louise Robinson, Martin McCabe
article en

Abstract

Background Psychiatric conditions are important survivorship outcomes among children and young people (CYP) diagnosed with cancer. However, many population-based studies have examined hospital contacts only, and estimates of absolute risk can be biased when competing mortality is not accounted for. We estimated absolute risks and relative hazards of clinically recorded anxiety and related disorders, depressive disorders, and first-time psychotropic prescribing. Methods We conducted a population-based matched retrospective cohort study across 1474 general practices in England using Clinical Practice Research Datalink Aurum primary care records linked to Hospital Episode Statistics Admitted Patient Care and mortality records. CYP diagnosed with malignant cancer or any central nervous system tumour at ages 0–24 years between Jan 1, 2000, and Dec 31, 2022, were matched by age, recorded sex, and general practice to up to 20 comparators without cancer at the index date. Primary outcomes were first recorded anxiety and related disorders and depressive disorders; secondary outcomes were first-time psychotropic prescribing. Individuals with pre-index records of the respective outcome were excluded from that outcome analysis. Follow-up ended at outcome occurrence, death, practice deregistration, last data collection, or Dec 31, 2022. We estimated cumulative incidence using the Aalen-Johansen estimator and ethnicity-adjusted cause-specific hazard ratios (HRs) using matched-set stratified Cox models. Findings There were 9145 CYP with cancer and 178709 comparators. Adjusted cause-specific HRs were 1.74 (95% confidence interval [CI] 1.61–1.88) for anxiety and related disorders, 1.16 (1.06–1.26) for depressive disorders, 1.27 (1.20–1.35) for antidepressant prescribing, 2.21 (2.05–2.38) for antipsychotic prescribing, and 2.69 (2.53–2.86) for anxiolytic prescribing. At 15 years, cumulative incidence was 14.1% (95% CI 13.0–15.3) versus 12.8% (12.5–13.1) for anxiety and related disorders, and 12.8% (11.6–14.0) versus 14.1% (13.8–14.5) for depressive disorders. Excess hazards were greatest in the early years after diagnosis. Interpretation CYP diagnosed with cancer had higher hazards of clinically recorded anxiety and related disorders, depressive disorders, and first-time psychotropic prescribing. These findings support proactive mental health monitoring and timely referral pathways within cancer and survivorship care, particularly early after diagnosis. Further research should evaluate whether timely assessment and tailored psychosocial support improve outcomes. Funding National Institute for Health and Care Research Manchester Biomedical Research Centre and Greater Manchester Patient Safety Research Collaboration.

EClinicalMedicineVol. 102
University of Manchester (GB), Manchester University NHS Foundation Trust (GB), The Christie Hospital (GB), The Christie NHS Foundation Trust (GB), NIHR Manchester Biomedical Research Centre (GB), Royal Manchester Children's Hospital (GB)
Good health and well-being
Childhood Cancer Survivors' Quality of Life
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon